maribavir (Livtencity)
Jump to navigation
Jump to search
Indications
- post-translplantation cytomegalovirus (CMV)
- treatment of adults & adolecents (>=12 years, weighing at least 35 kilograms) with post-transplant cytomegalovirus (CMV) infection/disease that does not respond to available antiviral treatment for CMV
Drug interactions
- may reduce the antiviral activity of ganciclovir & valganciclovir
- coadministration not recommended
Mechanism of action
- cytomegalovirus pUL97 kinase inhibitor
- inhibits CMV replication
More general terms
References
- ↑ FDA News Release. Nov 23, 2021 FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-common-type-post-transplant-infection-resistant-other-drugs
- ↑ Maertens J, Cordonnier C, Jaksch P et al Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. N Engl J Med 2019; 381:1136-1147 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31532960 https://www.nejm.org/doi/full/10.1056/NEJMoa1714656
- ↑ Mullard A FDA approves decades-old maribavir for CMV infection. Nature Reviews Drug Discovery. Dec 6, 2021 https://www.nature.com/articles/d41573-021-00208-2
- ↑ Wikipedia: Maribavir https://en.wikipedia.org/wiki/Maribavir